Reham Ajina
Reham Ajina
Assistant Professor, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
Verified email at
Cited by
Cited by
Advances in immunotherapy for glioblastoma multiforme
AB Mahmoud, R Ajina, S Aref, M Darwish, M Alsayb, M Taher, SA AlSharif, ...
Frontiers in Immunology, 6063, 2022
T-cell immunity in pancreatic cancer
R Ajina, LM Weiner
Pancreas 49 (8), 1014-1023, 2020
SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice
R Ajina, D Zamalin, A Zuo, M Moussa, M Catalfamo, SA Jablonski, ...
Oncoimmunology 8 (5), e1577127, 2019
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection
CW Shuptrine, R Ajina, EJ Fertig, SA Jablonski, HK Lyerly, ZC Hartman, ...
Cancer Immunology, Immunotherapy 66 (12), 1529-1544, 2017
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies
R Ajina, DJ Zahavi, YW Zhang, LM Weiner
Seminars in cancer biology 65, 28-37, 2020
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ...
Journal for ImmunoTherapy of Cancer 4 (1), 107-221, 2016
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
R Ajina, ZX Malchiodi, AA Fitzgerald, A Zuo, S Wang, M Moussa, ...
Cancer Immunology Research 9 (4), 386-400, 2021
Functional genomics: paving the way for more successful cancer immunotherapy
R Ajina, D Zamalin, LM Weiner
Briefings in functional genomics 18 (2), 86-98, 2019
Paediatric Asthma and the Microbiome: A Systematic Review
MG Aldriwesh, AM Al-Mutairi, AS Alharbi, HY Aljohani, NA Alzahrani, ...
Microorganisms 11 (4), 939, 2023
Cancer Immunotherapy
R Ajina, D Aldeghaither, S Jablonski, LM Weiner
Elsevier, 2017
SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
AA Alkayyal, R Ajina, M Cacciabue, AA Alkayyal, NH Saeedi, TH Alshehry, ...
Frontiers in Immunology 14, 278, 0
Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model íK
S Wang, A Fitzgerald, R Ajina, SA Jablonsk, LM Weiner, J MacDougall, ...
Cancer Research 80 (16 Supplement), 6636-6636, 2020
Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
R Ajina, A Zuo, S Wang, M Moussa, CJ Cooper, Y Shen, QR Johnson, ...
bioRxiv, 2020
Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer
JP Smith, S Wang, A Reham, SA Jablonski, LM Weiner
Cancer Research 76 (14 Supplement), 4023-4023, 2016
Repurposing the oncolytic virus VSV∆ 51M as a COVID-19 vaccine
AA Alkayyal, MM Darwish, R Ajina, SY Alabbas, MA Alotaibi, ...
Frontiers in Bioengineering and Biotechnology 11, 1150892, 2023
P-288 Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia
R Ajina, A Alhareeri, W Philip, N Alsekait, N Alarifi, H Alismail, ...
Annals of Oncology 34, S117, 2023
Outcomes of molecular tumor board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia
K Alshammari, F Sabatin, M Hazar-Rethinam, F Alotaibi, R Ajina, ...
Cancer Research 83 (7_Supplement), 938-938, 2023
Identifying Molecular Determinants of Immune Rejection in Pancreatic Cancer
RS Ajina
Georgetown University, 2020
Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure
L Weiner, R Ajina
Malignant pancreatic cancer cells respond to immune selection pressure to foster immunosuppression
R Ajina, A Zuo, M Moussa, SJ Cooper, Y Shen, QR Johnson, JM Parks, ...
Cancer Research 79 (13 Supplement), 4584-4584, 2019
The system can't perform the operation now. Try again later.
Articles 1–20